|
1
|
Polyak K: Heterogeneity in breast cancer.
J Clin Invest. 121:3786–3788. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Carey LA, Perou CM, Livasy CA, Dressler
LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S,
et al: Race, breast cancer subtypes, and survival in the Carolina
Breast Cancer Study. JAMA. 295:2492–2502. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Litzenburger BC and Brown PH: Advances in
Preventive Therapy for Estrogen-Receptor-Negative Breast Cancer.
Curr Breast Cancer Rep. 6:96–109. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Barcellos-Hoff MH: Does microenvironment
contribute to the etiology of estrogen receptor-negative breast
cancer? Clin Cancer Res. 19:541–548. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen JQ and Russo J: ERalpha-negative and
triple negative breast cancer: Molecular features and potential
therapeutic approaches. Biochim Biophys Acta. 1796:162–175.
2009.PubMed/NCBI
|
|
6
|
Shen K, Rice SD, Gingrich DA, Wang D, Mi
Z, Tian C, Ding Z, Brower SL, Ervin PR Jr, Gabrin MJ, et al:
Distinct genes related to drug response identified in ER positive
and ER negative breast cancer cell lines. PLoS One. 7:e409002012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bianchini G, Qi Y, Alvarez RH, Iwamoto T,
Coutant C, Ibrahim NK, Valero V, Cristofanilli M, Green MC,
Radvanyi L, et al: Molecular anatomy of breast cancer stroma and
its prognostic value in estrogen receptor-positive and -negative
cancers. J Clin Oncol. 28:4316–4323. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Milne RL, Kuchenbaecker KB, Michailidou K,
Beesley J, Kar S, Lindström S, Hui S, Lemaçon A, Soucy P, Dennis J,
et al: ABCTB Investigators; EMBRACE; GEMO Study Collaborators;
HEBON; kConFab/AOCS Investigators; NBSC Collaborators:
Identification of ten variants associated with risk of
estrogen-receptor-negative breast cancer. Nat Genet. 49:1767–1778.
2017. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Silva RL, Lopes AH, Guimarães RM and Cunha
TM: CXCL1/CXCR2 signaling in pathological pain: Role in peripheral
and central sensitization. Neurobiol Dis. 105:109–116. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang D, Yang W, Du J, Devalaraja MN, Liang
P, Matsumoto K, Tsubakimoto K, Endo T and Richmond A:
MGSA/GRO-mediated melanocyte transformation involves induction of
Ras expression. Oncogene. 19:4647–4659. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Balkwill FR: The chemokine system and
cancer. J Pathol. 226:148–157. 2012. View Article : Google Scholar
|
|
12
|
Acharyya S, Oskarsson T, Vanharanta S,
Malladi S, Kim J, Morris PG, Manova-Todorova K, Leversha M, Hogg N,
Seshan VE, et al: A CXCL1 paracrine network links cancer
chemoresistance and metastasis. Cell. 150:165–178. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Miyake M, Hori S, Morizawa Y, Tatsumi Y,
Nakai Y, Anai S, Torimoto K, Aoki K, Tanaka N, Shimada K, et al:
CXCL1-mediated interaction of cancer cells with tumor-associated
macrophages and cancer-associated fibroblasts promotes tumor
progression in human bladder cancer. Neoplasia. 18:636–646. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xu J, Zhang C, He Y, Wu H, Wang Z, Song W,
Li W, He W, Cai S and Zhan W: Lymphatic endothelial cell-secreted
CXCL1 stimulates lymphangiogenesis and metastasis of gastric
cancer. Int J Cancer. 130:787–797. 2012. View Article : Google Scholar
|
|
15
|
Wang Z, Wang Z, Li G, Wu H, Sun K, Chen J,
Feng Y, Chen C, Cai S, Xu J, et al: CXCL1 from tumor-associated
lymphatic endothelial cells drives gastric cancer cell into
lymphatic system via activating integrin β1/FAK/AKT signaling.
Cancer Lett. 385:28–38. 2017. View Article : Google Scholar
|
|
16
|
Kuo PL, Shen KH, Hung SH and Hsu YL:
CXCL1/GROα increases cell migration and invasion of prostate cancer
by decreasing fibulin-1 expression through NF-κB/HDAC1 epigenetic
regulation. Carcinogenesis. 33:2477–2487. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Han KQ, He XQ, Ma MY, Guo XD, Zhang XM,
Chen J, Han H, Zhang WW, Zhu QG and Zhao WZ: Targeted silencing of
CXCL1 by siRNA inhibits tumor growth and apoptosis in
hepatocellular carcinoma. Int J Oncol. 47:2131–2140. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang L, Zhang C, Xu J, Wu H, Peng J, Cai S
and He Y: CXCL1 gene silencing inhibits HGC803 cell migration and
invasion and acts as an independent prognostic factor for poor
survival in gastric cancer. Mol Med Rep. 14:4673–4679. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Divella R, Daniele A, Savino E, Palma F,
Bellizzi A, Giotta F, Simone G, Lioce M, Quaranta M, Paradiso A, et
al: Circulating levels of transforming growth factor-βeta (TGF-β)
and chemokine (C-X-C motif) ligand-1 (CXCL1) as predictors of
distant seeding of circulating tumor cells in patients with
metastatic breast cancer. Anticancer Res. 33:1491–1497.
2013.PubMed/NCBI
|
|
20
|
Zou A, Lambert D, Yeh H, Yasukawa K,
Behbod F, Fan F and Cheng N: Elevated CXCL1 expression in breast
cancer stroma predicts poor prognosis and is inversely associated
with expression of TGF-β signaling proteins. BMC Cancer.
14:7812014. View Article : Google Scholar
|
|
21
|
Wang L, Hou Y, Sun Y, Zhao L, Tang X, Hu
P, Yang J, Zeng Z, Yang G, Cui X, et al: c-Ski activates
cancer-associated fibroblasts to regulate breast cancer cell
invasion. Mol Oncol. 7:1116–1128. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-ΔΔC(T) method. Methods. 25:402–408. 2001. View Article : Google Scholar
|
|
23
|
Rhodes DR, Yu J, Shanker K, Deshpande N,
Varambally R, Ghosh D, Barrette T, Pandey A and Chinnaiyan AM:
ONCOMINE: A cancer microarray database and integrated data-mining
platform. Neoplasia. 6:1–6. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sorlie T, Tibshirani R, Parker J, Hastie
T, Marron JS, Nobel A, Deng S, Johnesn H, Pesich R, Geisler S, et
al: Repeated observation of breast tumor subtypes in independent
gene expression data sets. Proc Natl Acad Sci USA. 100:8418–8423.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Desmedt C, Piette F, Loi S, Wang Y,
Lallemand F, Haibe-Kains B, Viale G, Delorenzi M, ZhangY
d'Assignies MS, et al: Strong time dependence of the 76-gene
prognostic signature for node-negative breast cancer patients in
the TRANSBIG multicenter independent validation series. Clin Cancer
Res. 13:3207–3214. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhao J, Ou B, Han D, Wang P, Zong Y, Zhu
C, Liu D, Zheng M, Sun J, Feng H, et al: Tumor-derived CXCL5
promotes human colorectal cancer metastasis through activation of
the ERK/Elk-1/Snail and AKT/GSK3β/β-catenin pathways. Mol Cancer.
16:702017. View Article : Google Scholar
|
|
27
|
Fu XT, Dai Z, Song K, Zhang ZJ, Zhou ZJ,
Zhou SL, Zhao YM, Xiao YS, Sun QM, Ding ZB, et al:
Macrophage-secreted IL-8 induces epithelial-mesenchymal transition
in hepatocellular carcinoma cells by activating the
JAK2/STAT3/Snail pathway. Int J Oncol. 46:587–596. 2015. View Article : Google Scholar
|
|
28
|
Li S, Lu J, Chen Y, Xiong N, Li L, Zhang
J, Yang H, Wu C, Zeng H and Liu Y: MCP-1-induced ERK/GSK-3β/Snail
signaling facilitates the epithelial-mesenchymal transition and
promotes the migration of MCF-7 human breast carcinoma cells. Cell
Mol Immunol. 14:621–630. 2017. View Article : Google Scholar
|
|
29
|
Ou B, Zhao J, Guan S, Feng H, Wangpu X,
Zhu C, Zong Y, Ma J, Sun J, Shen X, et al: CCR4 promotes metastasis
via ERK/NF-κB/MMP13 pathway and acts downstream of TNF-α in
colorectal cancer. Oncotarget. 7:47637–47649. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jabłońska-Trypuć A, Matejczyk M and
Rosochacki S: Matrix metalloproteinases (MMPs), the main
extracellular matrix (ECM) enzymes in collagen degradation, as a
target for anticancer drugs. J Enzyme Inhib Med Chem. 31(Suppl 1):
177–183. 2016. View Article : Google Scholar
|
|
31
|
Nishio K, Motozawa K, Omagari D, Gojoubori
T, Ikeda T, Asano M and Gionhaku N: Comparison of MMP2 and MMP9
expression levels between primary and metastatic regions of oral
squamous cell carcinoma. J Oral Sci. 58:59–65. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zheng Y, Miu Y, Yang X, Yang X and Zhu M:
CCR7 mediates TGF-β1-induced human malignant glioma invasion,
migration, and epithelial-mesenchymal transition by activating
MMP2/9 through the nuclear factor kappaB signaling pathway. DNA
Cell Biol. 36:853–861. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chen SX, Yin JF, Lin BC, Su HF, Zheng Z,
Xie CY and Fei ZH: Upregulated expression of long noncoding RNA
SNHG15 promotes cell proliferation and invasion through regulates
MMP2/MMP9 in patients with GC. Tumour Biol. 37:6801–6812. 2016.
View Article : Google Scholar
|
|
34
|
Balkwill F: Cancer and the chemokine
network. Nat Rev Cancer. 4:540–550. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mantovani A, Savino B, Locati M, Zammataro
L, Allavena P and Bonecchi R: The chemokine system in cancer
biology and therapy. Cytokine Growth Factor Rev. 21:27–39. 2010.
View Article : Google Scholar
|
|
36
|
Zhang T, Tseng C, Zhang Y, Sirin O, Corn
PG, Li-Ning-Tapia EM, Troncoso P, Davis J, Pettaway C, Ward J, et
al: CXCL1 mediates obesity-associated adipose stromal cell
trafficking and function in the tumour microenvironment. Nat
Commun. 7:116742016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Freund A, Chauveau C, Brouillet JP, Lucas
A, Lacroix M, Licznar A, Vignon F and Lazennec G: IL-8 expression
and its possible relationship with estrogen-receptor-negative
status of breast cancer cells. Oncogene. 22:256–265. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lian S, Zhai X, Wang X, Zhu H, Zhang S,
Wang W, Wang Z and Huang J: Elevated expression of growth-regulated
oncogene-alpha in tumor and stromal cells predicts unfavorable
prognosis in pancreatic cancer. Medicine (Baltimore). 95:e43282016.
View Article : Google Scholar
|
|
39
|
Han KQ, Han H, He XQ, Wang L, Guo XD,
Zhang XM, Chen J, Zhu QG, Nian H, Zhai XF, et al: Chemokine CXCL1
may serve as a potential molecular target for hepatocellular
carcinoma. Cancer Med. 5:2861–2871. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Xiang Z, Jiang DP, Xia GG, Wei ZW, Chen W,
He Y and Zhang CH: CXCL1 expression is correlated with Snail
expression and affects the prognosis of patients with gastric
cancer. Oncol Lett. 10:2458–2464. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Cui X, Li Z, Gao J, Gao PJ, Ni YB and Zhu
JY: Elevated CXCL1 increases hepatocellular carcinoma
aggressiveness and is inhibited by miRNA-200a. Oncotarget.
7:65052–65066. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhou J, Yi L, Ouyang Q, Xu L, Cui H and Xu
M: Neurotensin signaling regulates stem-like traits of glioblastoma
stem cells through activation of IL-8/CXCR1/STAT3 pathway. Cell
Signal. 26:2896–2902. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhou B, Sun C, Li N, Shan W, Lu H, Guo L,
Guo E, Xia M, Weng D, Meng L, et al: Cisplatin-induced CCL5
secretion from CAFs promotes cisplatin-resistance in ovarian cancer
via regulation of the STAT3 and PI3K/Akt signaling pathways. Int J
Oncol. 48:2087–2097. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lin HY, Sun SM, Lu XF, Chen PY, Chen CF,
Liang WQ and Peng CY: CCR10 activation stimulates the invasion and
migration of breast cancer cells through the ERK1/2/MMP-7 signaling
pathway. Int Immunopharmacol. 51:124–130. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Xiong Y, Huang F, Li X, Chen Z, Feng D,
Jiang H, Chen W and Zhang X: CCL21/CCR7 interaction promotes
cellular migration and invasion via modulation of the MEK/ERK1/2
signaling pathway and correlates with lymphatic metastatic spread
and poor prognosis in urinary bladder cancer. Int J Oncol.
51:75–90. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Miyake M, Goodison S, Urquidi V, Gomes
Giacoia E and Rosser CJ: Expression of CXCL1 in human endothelial
cells induces angiogenesis through the CXCR2 receptor and the
ERK1/2 and EGF pathways. Lab Invest. 93:768–778. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Al-Alwan LA, Chang Y, Rousseau S, Martin
JG, Eidelman DH and Hamid Q: CXCL1 inhibits airway smooth muscle
cell migration through the decoy receptor Duffy antigen receptor
for chemokines. J Immunol. 193:1416–1426. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Filipovic R and Zecevic N: The effect of
CXCL1 on human fetal oligodendrocyte progenitor cells. Glia.
56:1–15. 2008. View Article : Google Scholar
|
|
49
|
Alaseem A, Alhazzani K, Dondapati P,
Alobid S, Bishayee A and Rathinavelu A: Matrix Metalloproteinases:
A challenging paradigm of cancer management. Semin Cancer Biol.
56:100–115. 2019. View Article : Google Scholar
|
|
50
|
Zeng L, Qian J, Zhu F, Wu F, Zhao H and
Zhu H: The prognostic values of matrix metalloproteinases in
ovarian cancer. J Int Med Res. May 17–2019.Epub ahead of print.
View Article : Google Scholar
|
|
51
|
Ren F, Tang R, Zhang X, Madushi WM, Luo D,
Dang Y, Li Z, Wei K and Chen G: Overexpression of MMP family
members functions as prognostic biomarker for breast cancer
patients: A systematic review and meta-snalysis. PLoS One.
10:e01355442015. View Article : Google Scholar
|
|
52
|
Bai L, Lin G, Sun L, Liu Y, Huang X, Cao
C, Guo Y and Xie C: Upregulation of SIRT6 predicts poor prognosis
and promotes metastasis of non-small cell lung cancer via the
ERK1/2/MMP9 pathway. Oncotarget. 7:40377–40386. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Wang Y, Wu N, Pang B, Tong D, Sun D, Sun
H, Zhang C, Sun W, Meng X, Bai J, et al: TRIB1 promotes colorectal
cancer cell migration and invasion through activation MMP-2 via
FAK/Src and ERK pathways. Oncotarget. 8:47931–47942.
2017.PubMed/NCBI
|
|
54
|
Robbins P, Pinder S, de Klerk N, Dawkins
H, Harvey J, Sterrett G, Ellis I and Elston C: Histological grading
of breast carcinomas: A study of interobserver agreement. Hum
Pathol. 26:873–879. 1995. View Article : Google Scholar : PubMed/NCBI
|
